Hospital stocks rebounded on Friday after the government capped trade margins on non-scheduled anti-cancer drugs at 30% of the maximum retail price. The regulation aims to reduce patient costs by an estimated ₹2,500 crore annually. While the move targets high price markups, analysts believe the impact on hospital earnings will be limited, as oncology drugs make up a small portion of overall revenue.
Hospital shares showed a recovery in Friday’s trading session as investors assessed the impact of the government’s new regulatory move. The National Pharmaceutical Pricing Authority (NPPA) has decided to cap trade margins on 110 non-scheduled anti-cancer drugs at 30% of the Maximum Retail Price (MRP). This decision comes after a recent period of market volatility for the sector, with the hospital index having dropped by 12% over the last two weeks amid concerns regarding drug pricing scrutiny.
The regulatory intervention addresses the high price mark-ups currently seen in the market. Industry data indicates that non-scheduled anti-cancer drugs often carry average trade margins of 170%, with some instances reaching as high as 700%. By limiting these margins to 30%, the government expects to lower retail prices for patients by 20% to 70%. The move is expected to lead to annual savings of approximately ₹2,500 crore for patients. Officials are currently working to finalize the official list of affected medicines, which is expected by October 14, 2026.
From an investor perspective, the market reaction appears to be driven by relief that the cap was set at 30%, which is widely viewed by analysts as a manageable regulatory adjustment. Prior to the announcement, there had been market fears of stricter price controls. According to various sector assessments, oncology medications typically contribute less than 5% to the total revenue of major hospital chains. Consequently, the impact on operating profit, or EBITDA, is estimated to be below 2.5%, which is seen as limited enough to be absorbed by hospital operators without significantly hurting their financial health.
Despite the positive stock market reaction, the sector remains under the spotlight. The broader issue of medicine pricing and hospital billing transparency continues to face legal and regulatory scrutiny. Investors may watch for whether this regulatory trend extends to other hospital consumables, as continued oversight in this area remains a key monitorable. While the immediate financial impact of this specific order appears contained, the environment remains sensitive to further policy updates regarding healthcare pricing. The next major update for market participants will be the official publication of the final list of drugs by the Directorate General of Health Services.